{"altmetric_id":1292253,"counts":{"readers":{"mendeley":33,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["100001293086029"],"posts_count":1},"total":{"posts_count":1}},"citation":{"altmetric_jid":"4f6fa50b3cf058f610003169","authors":["Alexandra Flemming"],"doi":"10.1038\/nrd3969","endpage":"189","first_seen_on":"2013-03-10T12:16:35+00:00","issns":["1474-1776","1474-1784"],"journal":"Nature Reviews Drug Discovery","last_mentioned_on":1362917760,"links":["http:\/\/www.nature.com\/nrd\/journal\/v12\/n3\/full\/nrd3969.html"],"pmid":"23449300","pubdate":"2013-03-01T00:00:00+00:00","publisher":"Nature Publishing Group","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"},{"name":"Biological Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"188","subjects":["pharmacology","drugtherapy"],"title":"Cancer: Double-pronged approach to combat mutant KRAS","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/cancer-doublepronged-approach-combat-mutant-kras"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":3628883,"mean":4.937418267118,"rank":2901688,"this_scored_higher_than_pct":2,"this_scored_higher_than":77473,"rank_type":"exact","sample_size":3628883,"percentile":2},"similar_age_3m":{"total_number_of_other_articles":85669,"mean":6.228638091236,"rank":65755,"this_scored_higher_than_pct":1,"this_scored_higher_than":310,"rank_type":"exact","sample_size":85669,"percentile":1},"this_journal":{"total_number_of_other_articles":1145,"mean":6.9910961538462,"rank":987,"this_scored_higher_than_pct":1,"this_scored_higher_than":14,"rank_type":"exact","sample_size":1145,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":44,"mean":6.1543720930233,"rank":40,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":44,"percentile":1}}},"demographics":{"users":{"mendeley":{"by_status":{"Researcher":18,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":9,"Other":2,"Student  > Master":1,"Student  > Bachelor":1,"Professor":1},"by_discipline":{"Engineering":2,"Medicine and Dentistry":1,"Chemistry":4,"Physics and Astronomy":1,"Agricultural and Biological Sciences":23,"Biochemistry, Genetics and Molecular Biology":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"mendeley":{"IE":1}}},"posts":{"facebook":[{"title":"http:\/\/www.nature.com\/nrd\/journal\/v12\/n3\/full\/nrd3969.html","url":"https:\/\/www.facebook.com\/100001293086029\/posts\/440887189323300","citation_ids":[1292253],"posted_on":"2013-03-10T12:16:00+00:00","summary":"Cancer: Double-pronged approach to combat mutant KRAS\n\nAlexandra Flemming\n\nAbstract\nAbout 20% of all cancers carry mutations in the GTPase KRAS, including 90% of pancreatic cancers. However, mutated KRAS has proven difficult to target with small molecules.","author":{"name":"Biologyfor You","url":"https:\/\/www.facebook.com\/100001293086029","facebook_wall_name":false,"image":"https:\/\/graph.facebook.com\/100001293086029\/picture","id_on_source":"100001293086029"}}]}}